Cathie Wood's ARK ETF published their daily trades for Tuesday, December 17th, 2024, revealing a continued strategy of actively managing their portfolio across various sectors. Leading the trades with the highest dollar value, ARK invested significantly in TEMPUS AI INC (NASDAQ:TEM), purchasing a total of 317,611 shares valued at $12,666,327. This move indicates ARK's growing interest in Tempus, a trend that has been observed over the past week with consistent acquisitions of the company's stock.
In addition to Tempus, ARK also increased its holdings in FUTU HOLDINGS LTD (NASDAQ:FUTU), buying 68,606 shares at a total value of $5,656,564. This purchase positions Futu as another key player in ARK's investment strategy for the day.
On the sell side, ARK divested notably from SHOPIFY INC (NYSE:SHOP), selling 31,078 shares with a total dollar value of $3,603,183. This sale represents the largest sell by dollar value for the day, suggesting a strategic shift away from Shopify (NYSE:SHOP)'s stock.
Other significant trades included buying 89,839 shares of BEAM THERAPEUTICS INC (NASDAQ:BEAM) for $2,599,042 and selling 15,862 shares of ADAPTIVE BIOTECHNOLOGIES CORP (NASDAQ:ADPT) for $1,075,443. ARK also sold 5,646 shares of COINBASE GLOBAL INC (NASDAQ:COIN) totaling $1,780,240 and 24,075 shares of IONIS PHARMACEUTICALS INC (NASDAQ:IONS) valued at $917,257.
Furthermore, ARK continued to adjust its portfolio with the acquisition of PACIFIC BIOSCIENCES OF CALIFORNIA INC (NASDAQ:PACB) and PERSONALIS INC (NASDAQ:PSNL), buying 340,996 and 63,678 shares at $699,041 and $236,245 respectively.
The trading activity reflects ARK's ongoing strategy of targeting innovative companies, particularly in the biotech and tech sectors, while also making adjustments based on performance and market trends. Investors following ARK's movements may find these trades indicative of the ETF's broader investment thesis, which often focuses on disruptive innovation and long-term growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.